MELBOURN, England, December 14, 2015 /PRNewswire/ --
Aegate, the world's leading provider of medicines authentication services, is pleased to announce an important milestone in the UK with the achievement of live scanning of medicines in community pharmacy. This important development has been accomplished in partnership with UK based CareMeds Ltd, a specialist Patient Management Record System developer.
(Logo: http://photos.prnewswire.com/prnh/20150610/748687 )
CareMeds Ltd supports community based pharmacists to provide a dispensing service in-store, through home delivery and to care homes, by providing a dispensing system unlike typical service providers.
Mark De Simone, Aegate CEO commented: "Aegate is proud to offer UK community pharmacy the opportunity to prepare to protect patients from falsified, counterfeit, recalled or expired medicines, and we are ready to support pharmacy professionals to achieve this goal. Working with an innovative organisation like CareMeds allows us to enhance patient safety while working with a team who are committed to delivering the best for their own customers."
John Rowley, CareMeds Managing Director added, "We are delighted to be working with Aegate and to be able to give added value to our customers through the application of Aegate's tried and tested service. Our system has been so successful because it improves the safety of medication administration at the patient bedside. Aegate's service raises the bar yet again." He continued, "Being ready for the requirements of the Falsified Medicines Directive is an important step for us and we have been pleased as to how efficient integration has been. Clearly being the first in the UK to validate packs in this way is a real coup for us."
By working with Aegate at this time, CareMeds will ensure that they and their customers can continue to operate efficiently, as manufacturers gradually change to the 2D data matrix bar code requirements of the Falsified Medicines Directive. There will be no surprises for CareMeds as they will be fully conversant with the latest authentication technology and processes.
The addition of community pharmacy in the UK complements the ground-breaking collaboration between Aegate, Oxford University Hospitals and Oxford Academic Health Science Network, to establish the optimum stage to authenticate for counterfeit medicines in secondary care using medicines authentication technology.
The introduction of the Falsified Medicines Directive requires medicines to be uniquely serialised, protected by tamper-proof seals and their authenticity verified before being supplied to patients. Every retail and hospital pharmacy in the EU will be obligated to have the ability to scan the serialised codes.
About Aegate
Aegate operates a highly secure real‐time service to verify the authenticity of medicines. This operates seamlessly from manufacturer to pharmacy, and has been independently certified as reliable, secure and 100% accurate. Aegate fully meets the requirements of a number of worldwide legislative efforts to combat falsified medicines, including the EU Falsified Medicines Directive, and is the only medicines authentication provider to provide a validated hospital authentication service, developed in collaboration with the University of Oxford. Aegate are also one of the chosen service providers for the National Blueprint Service available to stakeholders in European countries.
Aegate was established in 2003 and now has its authentication system operating in over 24,000 dispensing points. The Aegate service has checked over 3.5 billion medicine packs, helping to protect patients by alerting pharmacists to over 2.7 million packs of recalled, expired and possibly falsified or counterfeit medicines. Aegate has offices across Europe and North America and continues to grow year on year through international expansion.
For more information on Aegate, please visit http://www.aegate.com
Contact for the release:
Kelvin Bathe
Aegate Ltd
H9 The Courtyard
Melbourn Science Park
Melbourn
Herts
SG8 6HB
UK
Tel +44-(0)1763-268160
Share this article